top of page
RGOQ 2026 (5).png

Best Practices in Gynecologic Oncology 2026 

Advancing care in gynecologic oncology

GLOBAL LEARNING OBJECTIVES

At the end of this CPD activity, participants will be able to

  • assess their knowledge and practice in the management of gynecologic cancers in light of current evidence, recent guidelines, and discussions of complex clinical cases; 

  • identify gaps between their current practice and best practices in gynecologic oncology, particularly with respect to the integration of biomarkers, the selection of multimodal treatments, innovative surgical approaches, and patients’ quality of life; 

  • determine concrete and applicable practice improvement strategies to optimize personalized, safe, interdisciplinary, and equitable care for patients with gynecologic cancers. 

This activity is an accredited group learning activity (Section 1), as defined by the Maintenance of Certification (MOC) program of the Royal College of Physicians and Surgeons of Canada, as well as a recognized professional development activity (Category A), as defined by the Collège des médecins du Québec. This activity has been approved by the Continuing Professional Development Directorate (CPDD) of the Fédération des médecins spécialistes du Québec.

 

You may claim a maximum of 7.25 hours under Section 1 / recognized professional development activity (Category A). Participants must claim a number of hours corresponding to the duration of their participation.

 

This activity is an accredited self-assessment program (Section 3), as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, as well as a recognized practice assessment activity (Category B), as defined by the Collège des médecins du Québec. This activity has been approved by the Continuing Professional Development Directorate (CPDD) of the Fédération des médecins spécialistes du Québec.

Pre- and Post-Test: Best Practices in Gynecologic Oncology 2026

You may claim a maximum of 3 hours under Section 3 / recognized practice assessment activity (Category B). Participants must claim a number of hours corresponding to the duration of their participation.

RGOQ 2026 (6).png
Next Meetup

The event program may be subject to minor changes at the discretion of the scientific committee.

Programme

SATURDAY, JUNE 13, 2026

7:15-8:00

Networking Breakfast

8:00-9:15 

Advanced and Metastatic Endometrial Cancer 

Learning Objectives

At the end of this session, participants will be able to: 

  • integrate the FIGO 2024 classification, including molecular classification, into the assessment and management of advanced and metastatic endometrial cancer; 

  • select personalized treatment strategies based on the patient’s clinical, pathological, and molecular profile; 

  • recognize approaches that may reduce treatment-related toxicity and preserve quality of life in women with advanced and metastatic endometrial cancer. 

Dr. Marie-Claude Renaud and Dr. Alexandra Sebastianelli, CHU de Québec 

9:15-10:30

Vulvar Cancer

Learning Objectives

At the end of this session, participants will be able to: 

  • analyze the indications for and limitations of multimodal therapeutic strategies in the treatment of vulvar cancer; 

  • recognize the current and potential role of biomarkers in individualizing care; 

  • determine approaches aimed at reducing treatment-related morbidity and improving patients’ quality of life. 

Dr. Céline Lechartier, gynecologic oncologist, and Dr. Hugo Villeneuve, radiation oncologist, CIUSSS du Saguenay–Lac-Saint-Jean

10:30-11:00

Networking Break

11:00-12:15

Recurrent Ovarian Cancer: Platinum-Sensitive and Platinum-Resistant Disease 

Learning Objectives

At the end of this session, participants will be able to: 

  • compare treatment strategies according to whether recurrence is platinum-sensitive or platinum-resistant; 

  • recognize biomarkers that are useful for treatment selection and for estimating therapeutic response; 

  • identify strategies to overcome treatment resistance while taking patients’ quality of life into account. 

Dr. Élizabeth Tremblay, gynecologic oncologist, CHUM

12:15-13:15

Lunch

13:15-14:30

Locally Advanced and Recurrent Cervical Cancer 

Learning Objectives

At the end of this session, participants will be able to: 

  • analyze the best multimodal treatment options for patients with locally advanced or recurrent cervical cancer; 

  • integrate biomarkers and relevant clinical characteristics into treatment personalization; 

  • recognize interventions that may reduce treatment-related morbidity and improve patients’ quality of life. 

Dr. Paul Bessette, gynecologic oncologist, CHU Sherbrooke

14:30-15:45

Innovative Surgical Approaches and Ovarian Cancer 

Learning Objectives

At the end of this session, participants will be able to: 

  • assess the indications, benefits, and limitations of cardiophrenic lymph node resection in ovarian cancer cytoreduction; 

  • analyze the technical principles and safety considerations associated with complex diaphragmatic surgery; 

  • recognize the contribution of advanced technologies to the planning and performance of extensive cytoreduction. 

Dr. Lucas Sideris

15:45-16:15

Networking Break

16:15-17:15

Tumour Board

Learning Objectives

At the end of this session, participants will be able to: 

  • analyze, through complex clinical cases, optimal integrative strategies applicable in gynecologic oncology in 2026; 

  • assess the contribution of an interdisciplinary approach to decision-making and care optimization; 

  • identify organizational, clinical, or systemic limitations that influence the delivery of care to patients with gynecologic cancer and determine opportunities for improvement. 

Dr. Léonie Dallaire-Nantel, CIUSSS du Saguenay–Lac-Saint-Jean

17:15

Closing Remarks

SPEAKERS

Paul Bessette, MD
Gynecologic Oncologist, Researcher and Full Professor
CIUSSS de l’Estrie – CHUS, Faculty of Medicine and Health Sciences, Université de Sherbrooke

Dr. Paul Bessette completed his medical studies, residency in obstetrics and gynecology, and fellowship in gynecologic oncology at Université de Montréal. Since 1995, he has practised as an obstetrician-gynecologist and gynecologic oncologist within the Estrie suprarregional interdisciplinary team for the fight against gynecologic cancers (ISEL-CCG), at the Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS). He is a Full Professor in the Department of Obstetrics and Gynecology at the Faculty of Medicine and Health Sciences of Université de Sherbrooke, where he also served as Head of the Gynecologic Oncology Service. A researcher and founding member of the Cancer: Biology, Prognosis and Diagnosis Axis at the CHUS Research Centre, he is also a founding member and former president of the Regroupement des gynécologues-oncologues du Québec (RGOQ). Profile: [https://www.usherbrooke.ca/recherche/fr/specialistes/details/paul.bessette](https://www.usherbrooke.ca/recherche/fr/specialistes/details/paul.bessette)

Paul.png

Alexandra Sebastianelli, MD
Gynecologic Oncologist
CHU de Québec – Université Laval

Dr. Alexandra Sebastianelli is a gynecologic oncologist at CHU de Québec – Université Laval, Hôtel-Dieu de Québec, where she has been practising since 2010. She obtained her degree in obstetrics and gynecology from Université Laval in 2008, before completing a fellowship in gynecologic oncology at Université de Montréal in 2010. In 2016, she also completed a microprogram in university pedagogy in health sciences at Université Laval. Dr. Sebastianelli plays a key role in the training and education of future physicians. She is the Director of the Gynecologic Oncology Fellowship Program at Université Laval and an AMCEL Associate Professor in the Department of Obstetrics and Gynecology at the same university. She has also made significant contributions to the Society of Gynecologic Oncology of Canada, where she served as a member of the Guidelines Committee from 2012 to 2021, and as Chair of the committee from 2019 to 2020. She currently chairs the Regroupement des gynécologues-oncologues du Québec (RGOQ) and is responsible for the MED-1223 course on the female reproductive system at Université Laval. In addition to her academic responsibilities, Dr. Sebastianelli is a principal investigator and co-investigator on several Phase 2 and 3 research protocols at CHU de Québec – Université Laval. Her main areas of interest include ovarian cancer, gestational trophoblastic disease and medical education, fields in which she contributes to the advancement of knowledge and clinical practice.

A.Sebastianelli.png

Elizabeth Tremblay, MD
Gynecologic Oncologist
CHUM

Elizabeth Tremblay completed her fellowship training in gynecologic oncology at the CHUM, then pursued a second clinical fellowship in peritoneal surgery at Dalhousie University. She joined the CHUM team as a gynecologic oncologist in 2023. Her clinical interests focus on the medical and surgical management of ovarian neoplasms.

Tremblay.png

Conflict of interest coming soon

Lucas Sideris, MD, FRCSC
General Surgical Oncologist, Associate Professor
Université de Montréal

Dr. Sideris completed his medical studies at Université Laval and obtained his MD in 1997. He completed his specialty training in general surgery at Université de Montréal and received his certification from the Royal College of Physicians and Surgeons of Canada in 2002. He then pursued postdoctoral training through a fellowship at the Gustave Roussy Institute in Paris, which he completed in 2004, and obtained a diploma in clinical carcinology from Université Paris XI. In 2011, he obtained certification as a general surgical oncologist from the Collège des médecins du Québec. His areas of interest and expertise include peritoneal surface malignancies, breast diseases, clinical research and surgical education. From 2016 to 2025, he served as Director of the Surgical Foundations Program at Université de Montréal. He is currently Director of Residency Programs for the Surgery and Obstetrics-Gynecology cluster at Université de Montréal, as well as Director of the provincial peritoneal surface malignancies network within the Programme québécois de cancérologie.

Sideris.png

Marie-Claude Renaud, MD
Gynecologic Oncologist
CHU de Québec – Université Laval

Dr. Renaud completed her medical training and residency at Université Laval. She then pursued subspecialty training in gynecologic oncology at Université de Montréal. She has been practising gynecologic oncology in Québec City since completing her training. Her current areas of clinical interest include minimally invasive surgery and robotic surgery. She is Chief of the Gynecologic Oncology Service and Chief of the Clinical Department of Obstetrics and Gynecology at CHU de Québec-Université Laval.

No image female.png

Hugo Villeneuve
Radiation Oncologist
CIUSSS du Saguenay–Lac-Saint-Jean, Hôpital de Chicoutimi

Dr. Hugo Villeneuve graduated from medical school in 2007. He completed his residency in radiation oncology at the Université de Montréal in 2012. He then began practicing radiation oncology at the CIUSSS du Saguenay–Lac-Saint-Jean, Hôpital de Chicoutimi, where his clinical activities focus on gynecologic and prostate radiotherapy. His particular interest in brachytherapy has led him to contribute to the development of gynecologic interstitial treatments within his institution. Alongside his clinical practice, he is also involved in several medical-administrative and teaching committees, including the CMDP, of which he has been president for the past four years.

No image male.png

Léonie Dallaire-Nantel, MD
Gynecologic Oncologist
Hôpital de Chicoutimi

Dr. Léonie Dallaire-Nantel is a gynecologic oncologist at CIUSSS du Saguenay–Lac-Saint-Jean. She completed her medical studies at Université Laval and her specialization in obstetrics and gynecology at Université de Sherbrooke. She also completed a two-year fellowship in gynecologic oncology at Université Laval. During her training, she took part in international clinical rotations in Senegal and Mali, and was also involved in various research projects and scientific publications.

Nantel.png

Céline Lechartier, MD
Gynecologic Oncologist
CIUSSS du Saguenay–Lac-Saint-Jean

She is a specialist physician in gynecologic oncology and holds a State Diploma of Doctor of Medicine from Université de Nantes in France, obtained in 2017. Her thesis focused on advanced ovarian cancer (FIGO stage III) and the prognostic impact of retroperitoneal lymph node involvement. That same year, she also obtained her Diploma of Specialized Studies (DES) in obstetrics and gynecology, following a residency completed between 2012 and 2017. From 2017 to 2020, she practised in gynecologic oncology in France, developing clinical expertise in the management of gynecologic cancers. During this period, she also completed additional training through a Diploma of Complementary Specialized Studies (DESC) in oncology, which she obtained in 2020. Driven by a desire to broaden her skills and take on new international challenges, she then crossed the Atlantic to pursue subspecialty training in gynecologic oncology through a fellowship at Université Laval in Québec, Canada. This led to her certification by the Royal College in gynecologic oncology. Since 2024, she has been practising as a gynecologic oncologist in the Saguenay region, where she is actively involved in the care of patients with gynecologic cancers in a regional setting.

Celine.png

Scientific Committee

Nantel.png

Léonie Dallaire-Nantel

Gynecologic Oncologist

HÔPITAL DE CHICOUTIMI

Léonie Dallaire-Nantel is a gynecologic oncologist at the CIUSSS du Saguenay-Lac-Saint-Jean. She completed her medical studies at Université Laval and her residency in obstetrics and gynecology at the Université de Sherbrooke. She also completed a two-year fellowship in gynecologic oncology at Université Laval. During her training, she took part in international placements in Senegal and Mali and was also involved in various research projects and scientific publications.

No image male.png

Alexandre Rozenholc

Gynecologic Oncologist

CISSS DE L'OUTAOUAIS

Biography coming soon

S.Fortin (1).png

Suzanne Fortin

Gynecologic Oncologist

HÔPITAL MAISONNEUVE-ROSEMONT

Dr. Suzanne Fortin received her medical degree from the Université de Montréal in 2003. She continued her training with a specialized diploma in obstetrics and gynecology at the same institution, which she completed in 2008. Her interest in gynecologic neoplasms led her to pursue a fellowship in gynecologic oncology at the CHUM, Université de Montréal, in 2010. Passionate about research, Dr. Fortin is dedicated to the study of gynecologic neoplasms. She is also highly active clinically, working at the gynecologic oncology clinic. She specializes in major oncologic and minimally invasive surgeries, particularly laparoscopic procedures. In addition to her surgical expertise, she also practices colposcopy. Dr. Fortin also plays an important role in the management of academic activities. She is responsible for the obstetrics and gynecology clerks at Hôpital Maisonneuve-Rosemont (HMR), where she shares her knowledge and experience with the next generation of physicians.

A. Sebatianelli.png

Alexandra Sebastianelli

Gynecologic Oncologist

HÔTEL DIEU DE QUÉBEC (HDQ)

Dr. Alexandra Sebastianelli is an experienced gynecologic oncologist who has been practicing at CHU de Québec, Hôtel-Dieu de Québec since 2010. She received her degree in Obstetrics and Gynecology from Université Laval in 2008, before pursuing a fellowship in Gynecologic Oncology at the Université de Montréal, which she completed in 2010. In 2016, she further enriched her training by completing a microprogram in university pedagogy for health sciences at Université Laval. Dr. Sebastianelli plays a key role in the training and education of future physicians. She is the Director of the Gynecologic Oncology Fellowship Program at Université Laval and an AMCEL Associate Professor in the Department of Obstetrics and Gynecology at the same institution. She has also made significant contributions to the Society of Gynecologic Oncology of Canada, where she served as a member of the Guidelines Committee from 2012 to 2021 and as Chair of that committee from 2019 to 2020. She is currently President of the Regroupement des gynécologues oncologues du Québec and is responsible for the MED1223 course on the female reproductive system at Université Laval. In addition to her academic responsibilities, Dr. Sebastianelli is the principal investigator and co-investigator of several Phase 2 and Phase 3 research protocols at CHU de Québec. Her main areas of interest include ovarian cancer, gestational trophoblastic disease, and medical education, fields in which she continually strives to advance knowledge and clinical practice.

Lau.png

Susie Lau

Gynecologic Oncologist

McGill

Dr. Susie Lau is an Assistant Professor appointed to the Departments of Oncology and Obstetrics and Gynecology at McGill University. She earned her medical degree from McMaster University in Hamilton, Ontario. She then completed her residency in Obstetrics and Gynecology at McGill University in Montreal, Quebec, and became certified by the Royal College in Obstetrics and Gynecology. She subsequently completed a Royal College-approved fellowship in Gynecologic Oncology at the Université de Montréal. At the completion of her clinical training at the Université de Montréal in 2003, she returned to the McGill University Health Centre as an attending gynecologic oncologist and joined the Gynecologic Oncology Division at the Segal Cancer Centre / Sir Mortimer B. Davis Jewish General Hospital in 2005. She earned a Master of Science degree in Epidemiology and Biostatistics from McGill University in 2008. She is the former President of the Regroupement des Gynécologues Oncologues du Québec (RGOQ). She has also served as Director of the Gynecologic Oncology Fellowship Program at McGill since 2012. She is an active member of the Royal College Training Committee, which helps shape the future of training programs in her subspecialty, and is also a member of the Royal College Subspecialty Examination Committee. Her research interests are diverse and include novel experimental treatments and clinical trials in gynecologic cancers, as well as the application of robot-assisted minimally invasive surgery in gynecologic oncology.

Conflict of Interest coming soon

Venue

Université du Québec à Trois-Rivières (UQTR)
3351 Boulevard des Forges
Trois-Rivières, Quebec G8Z 4M3

Participants are invited to enter through the main entrance located on Avenue Gilles-Boulet, Door B1. This entrance provides direct access to the main hall and the amphitheatre.

Parking is available in Parking Lot P2.

The campus map is available below. The recommended entrance is circled in black.
 

Plan du campus.jpg

Sponsors

This activity has received an educational grant from Merck, GSK, AbbVie and Eisai. 
The RGOQ sincerely appreciates the continued support of its sponsors in advancing gynecologic oncology care and women’s health.

Become Our Partner

RGOQ is the partner of choice for healthcare organizations, hospitals, patient advocacy groups, pharmaceutical companies, and medical device manufacturers that share our vision and commitment. By partnering with us, you join a network of professionals and organizations dedicated to improving patient outcomes and advancing the field of gynecologic oncology.​

bottom of page